StemCyte Overview
- Founded
-
1997
- Status
-
Private
- Employees
-
109
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
StemCyte General Information
Description
Operator of a regenerative cell therapy company intended to focus on stem cell therapy and regenerative medicine. The company has established an inventory of genetically diverse cord blood banks as the feedstuff, it has utilized the same cord tissue products to develop a proprietary regenerative therapy platform technology, enabling physicians to cure life-threatening diseases such as spinal cord injury, chronic/acute stroke, cartilage repair, and other neurological disorders.
Contact Information
Website
www.stemcyte.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Primary Office
- 13800 Live Oak Avenue
- Baldwin Park, CA 91706
- United States
+1 (866) 000-0000
StemCyte Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Secondary Transaction - Private | 08-Mar-2022 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
| 10. Later Stage VC | 000.00 | Completed | Clinical Trials - Phase 2 | |||
| 9. Secondary Transaction - Private | 000.00 | Completed | Generating Revenue | |||
| 8. Debt - General | 23-Nov-2010 | 000.00 | Completed | Generating Revenue | ||
| 7. Debt - General | 01-Jun-2009 | 000 | 000.00 | Completed | Generating Revenue | |
| 6. Later Stage VC | 02-Oct-2007 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series 3) | 14-Jul-2006 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series D) | 20-May-2002 | 00.000 | 000.00 | 0000 | Completed | Startup |
| 3. Later Stage VC (Series C) | 14-Feb-2002 | $7.4M | $12.9M | 00000 | Completed | Startup |
| 2. Early Stage VC (Series B) | 02-Oct-2000 | $5.46M | $5.46M | 000.00 | Completed | Startup |
StemCyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series C | 000,000 | 00.000000 | 00 | 000 | 000 | 00 | 00.00 | 0.000 |
| Series B | 1,821,000 | $0.001000 | 7% | $3 | $3 | 1x | $2.5 | 11.51% |
| Series A | 1,850,000 | $0.001000 | 7% | $2.5 | $2.5 | 1x | $1 | 24.36% |
StemCyte Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a regenerative cell therapy company intended to focus on stem cell therapy and regenerative medicine. The co
Biotechnology
Baldwin Park, CA
109
As of 2022
000.00
00000000000
000.00
000000
t esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
00000 0000000000 00000000
Waltham, MA
000000&0
000000
lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
00000 0000000000 00000000
Chennai, India
0000
As of 0000
00.000
0000000000 0
00.000
Add Comparison
StemCyte Competitors (5)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Viacord | Corporate Backed or Acquired | Waltham, MA | 000000&0 | |||
| 00000000 000000000 | Venture Capital-Backed | Chennai, India | 0000 | 00.000 | 0000000000 0 | 00.000 |
| 0000 00000 0000000 | Formerly PE-Backed | Los Angeles, CA | 000 | 00000 | 000000000000 | |
| 00000000 00000 | Formerly PE-Backed | Singapore, Singapore | 000 | 000.00 | 000000000 | 000.00 |
| 0000-0000 00000000 | Corporation | Oldsmar, FL | 00 | 00000 | 000000&0 |
StemCyte Patents
StemCyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3137570-A1 | High concentration cell packaging and shipping | Pending | 15-May-2019 | 0000000000 | |
| US-20120034197-A1 | Hiv-resistant stem cells and uses thereof | Abandoned | 09-Apr-2009 | 000000000 | 00 |
| US-20140227236-A1 | Hiv-resistant stem cells and uses thereof | Abandoned | 09-Apr-2009 | 000000000 | 0 |
| US-20080008693-A1 | Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use | Granted | 02-Jun-2005 | 0000000000 | 0 |
| US-8048619-B2 | Method of treating a hematopoietic associated disease or disorder with plasma-depleted, but not erythrocyte-depleted cord blood compositions | Active | 02-Jun-2005 | C12N5/0647 | 00 |
StemCyte Executive Team (10)
StemCyte Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Chris Tsai | Self | Board Member | 000 0000 |
| Eli Wang | Self | Board Member | 000 0000 |
| George Lee Ph.D | Amkey Ventures | Board Member | 000 0000 |
| Jonas Wang Ph.D | StemCyte | Chief Executive Officer, President & Chairman | 000 0000 |
| Kenneth Giacin | Self | Chief Business Advisor & Vice Chairman | 000 0000 |
StemCyte Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
StemCyte Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Amkey Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Fairbridge Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Kenson Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Kuwait Life Sciences Company | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Montage Capital | Mezzanine | Minority | 000 0000 | 000000 0 |